5-bromo-1,3-dimethyluracil is a brominated uracil derivative. It is a key intermediate in the synthesis of various uracil-based compounds. Its importance lies in its potential as a building block for pharmaceuticals, agrochemicals, and other functional materials. Research on this compound focuses on its synthesis, its ability to modulate biological processes, and its potential applications in different fields. The specific effects and importance of 5-bromo-1,3-dimethyluracil depend on the context of its use and the research being conducted.'
5-bromo-1,3-dimethyluracil: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 81494 |
| SCHEMBL ID | 1527119 |
| MeSH ID | M0170361 |
| Synonym |
|---|
| 7033-39-8 |
| AKOS005431541 |
| 5-bromo-1,3-dimethyl-2,4(1h,3h)-pyrimidinedione |
| AG-670/02635045 |
| 5-bromo-1,3-dimethyluracil, 98% |
| SR-01000644535-1 |
| inchi=1/c6h7brn2o2/c1-8-3-4(7)5(10)9(2)6(8)11/h3h,1-2h |
| STK386911 |
| 5-bromo-1,3-dimethylpyrimidine-2,4(1h,3h)-dione |
| HMS1664P08 |
| 1,3-dimethyl-5-bromouracil |
| 5-bromo-1,3-dimethylpyrimidine-2,4-dione |
| 5-bromo-1,3-dimethyluracil |
| 2,4(1h,3h)-pyrimidinedione, 5-bromo-1,3-dimethyl- |
| CCG-55513 |
| 5-bromo-1,3-dimethyl-1h-pyrimidine-2,4-dione |
| DTXSID70220612 |
| mfcd00191846 |
| SCHEMBL1527119 |
| uracil, 5-bromo-1,3-dimethyl- |
| 5-bromo-1,3-dimethyl-2,4(1h,3h)-pyrimidinedione # |
| DS-4568 |
| 4-(4-pentylphenyl)cyclohexanone |
| CS-0089808 |
| D74897 |
| A866630 |
| SB60550 |
| 5-bromo-1,3-dimethyl-pyrimidine-2,4-dione |
| SY101544 |
| 5-bromo-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione |
| EN300-269988 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.89) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||